Article
De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
Cancer science - 1 Jan 2014
Tokunaga Takashi, Tomita Akihiro, Sugimoto Keiki, Shimada Kazuyuki, Iriyama Chisako, Hirose Tatsuya, Shirahata-Adachi Mizuho, Suzuki Yasuhiro, Mizuno Hiroki, Kiyoi Hitoshi, Asano Naoko, Nakamura Shigeo, Kinoshita Tomohiro, Naoe Tomoki
Abstract excerpt
CD20 is expressed in most B-cell lymphomas and is a critical molecular target of rituximab. Some B-cell lymphomas show aberrant CD20 expression, and rituximab use in these patients is controversial. Here we show both the molecular mechanisms and the clinical significance of de novo diffuse large B-cell lymphomas (DLBCL) that show a CD20 immunohistochemistry (IHC)-positive and flow cytometry (FCM)- negative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.